首页> 外文期刊>Journal of Drug Delivery and Therapeutics >DEVELOPMENT AND CHARACTERIZATION OF SRM MICROSPHERES OF REPAGLINIDE
【24h】

DEVELOPMENT AND CHARACTERIZATION OF SRM MICROSPHERES OF REPAGLINIDE

机译:瑞格列奈SRM微球的开发与表征

获取原文
           

摘要

The aim of current work to develop and evaluate sustained release mucoadhesive (SRM) microspheres of Repaglinide using emulsification solvent evaporation technique. Effects of formulation variables i.e. polymer concentration and phase volume ratio on particle size, % mucoadhesion and drug release were investigated in this study. Scanning electron microscopy of microspheres with maximum drug content (Formulation CH1:8) demonstrated smooth surface spherical particles with mean diameter of 64.78 ± 3.26 μm. The mean Particle size, % drug loading and mucoadhesion were found to vary by changing the formulation variables. Microspheres size was significantly increased as increasing the polymer concentration in the aqueous phase while size of microspheres decrease as increase in volume of continuous phase. Decrease in size of microspheres leads to decrease in mucoadhesion time, % drug loading and faster the drug release. It can be concluded that the present mucoadhesive microspheres can be an ideal system to deliver the Repaglinide in sustained release manner for management of Type II Diabetes Mellitus.
机译:当前工作的目的是使用乳化溶剂蒸发技术开发和评估瑞格列奈缓释粘膜粘附(SRM)微球。在这项研究中,研究了配方变量(即聚合物浓度和相体积比)对粒径,粘膜粘附%和药物释放的影响。具有最大药物含量(配方CH1:8)的微球的扫描电子显微镜显示,表面光滑的球形颗粒平均直径为64.78±3.26μm。发现平均粒径,%载药量和粘膜粘附力通过改变配方变量而变化。随着水相中聚合物浓度的增加,微球的尺寸显着增加,而随着连续相体积的增加,微球的尺寸减小。微球尺寸的减小导致粘膜粘着时间的减少,药物载量的百分比降低以及药物释放更快。可以得出结论,本发明的粘膜粘附性微球可以是以持续释放方式递送瑞格列奈用于治疗II型糖尿病的理想系统。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号